To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the world understands ultra-processed foods, after more than 90 independent food ...

NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...

Gift 5 articles to anyone you choose each month when you subscribe. Danish pharmaceutical giant Novo Nordisk says about 13 million Australians are living with obesity or are overweight ...

Novo Nordisk is planning to open an artificial intelligence (AI) research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations.